Hot Deals:
amol minechem 601.00 (0.17 %) anglo french drugs 930.00 (3.33 %) anugraha valve 280.00 (1.82 %) apl metals 40.00 (-2.44 %) apollo fashion 107.00 (1.90 %) archit nuwood 500.00 arkfin investments 50.00 arohan 202.00 (1.00 %) assam carbon 265.00 (1.92 %) avalokiteshvar 242.00 (0.83 %) axles india 610.00 (1.67 %) balmer lawrie 202.00 (1.00 %) bharat hotels 345.00 (1.47 %) bima mandi 235.00 (-2.08 %) bira 555.00 (-0.89 %) boat 1,380.00 (-1.43 %) c & s electric 840.00 (-1.18 %) cable corporation 13.00 (-0.76 %) capgemini 11,900.00 (0.85 %) care health 186.00 (-1.59 %) carrier aircon 545.00 (-0.91 %) cial 326.00 (0.31 %) csk 170.00 (-1.16 %) dalmia refract 260.00 (1.96 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 440.00 (3.53 %) electronica plastic 2,100.00 (-0.99 %) elgi ultra 400.00 elofic 2,100.00 (2.44 %) esl steel 46.00 (1.10 %) fincare business 86.00 (3.61 %) fincare sfbl 205.00 (1.49 %) fino paytech 133.00 (-1.48 %) flipkart india 231,001.00 (0.00 %) frick india 15,600.00 (-0.95 %) gkn driveline 1,325.00 (-0.38 %) godavari bio 71.00 (1.43 %) goodluck defence 235.00 (2.17 %) group pharma 300.00 gynofem healthcare 63.00 (-3.08 %) hazira cargo terminals limited 205.00 (1.49 %) hdb financial 1,120.00 (-0.88 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,300.00 (-1.74 %) hella india 910.00 (1.11 %) hero fincorp 1,990.00 (-0.50 %) hexaware 700.00 (-2.78 %) hicks 1,450.00 (2.11 %) hira ferro 180.00 (2.86 %) honeywell electrical 6,200.00 (1.64 %) ikf finance 312.00 (0.65 %) incred financial 10.00 (1.01 %) incred holdings 165.00 (-1.79 %) india carbon 1,135.00 (-1.30 %) india exposition 121.00 (0.83 %) indian potash 3,250.00 (1.56 %) indian seamless 175.00 (2.94 %) indo alusys 25.75 (-0.96 %) indofil 1,030.00 (0.49 %) infinite computer 405.00 (1.25 %) inkel 29.00 (-3.33 %) jana small finance bank 75.00 kel 610.00 (-2.40 %) kial 126.00 (-1.56 %) klm axiva 15.75 (1.61 %) kurlon limited 1,255.00 (0.40 %) lava 49.00 (-2.00 %) mahindra rural mrhfl 100.00 manipal housing 74.00 (2.07 %) manjushree technopack 3,050.00 (0.66 %) martin & harris 975.00 (-1.52 %) matrix gas 950.00 (-1.04 %) merino 3,350.00 (1.52 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 410.00 (-2.38 %) mobikwik 595.00 (-0.34 %) mohan meakin 2,150.00 (2.38 %) mohfl 13.60 (-0.73 %) msei 1.15 (-0.86 %) msil 36.00 (2.86 %) nayara energy 595.00 (-0.83 %) nayara energy ncd 315.00 (3.28 %) ncdex 220.00 (-0.90 %) ncl buildtek 310.00 (3.33 %) ncl holdings 92.00 (1.10 %) northern arc 400.00 nsdl 825.00 (1.85 %) nse 5,700.00 (1.79 %) orbis financial 340.00 (0.29 %) oswal minerals 60.10 (-1.48 %) otis 3,700.00 (-0.67 %) oyo 43.50 (-1.14 %) panasonic appliances 262.00 (0.77 %) paymate india 520.00 (-0.95 %) pharmeasy 8.50 (-2.30 %) pharmed limited 480.00 (2.13 %) philips domestic 720.00 (-1.37 %) philips india 910.00 (-1.09 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 255.00 (-1.92 %) rapido 16,650.00 (0.03 %) rasoi 31,500.00 (0.32 %) reliance gic 505.00 (1.00 %) resins plastics 475.00 (3.26 %) ring plus aqua 530.00 (0.95 %) rrl 1,275.00 (2.00 %) rrp s4e innovation 345.00 (-1.43 %) sab miller 490.00 (2.94 %) sbi amc 2,170.00 (0.93 %) sbi general insurance 620.00 (3.33 %) scottish assam 480.00 (2.13 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,310.00 (-1.50 %) smile microfinance 55.00 (1.85 %) sterlite power 748.00 (-0.27 %) studds 915.00 (-1.08 %) svsml 315.00 (2.94 %) swiggy 355.00 (1.43 %) t stanes 810.00 (1.25 %) tata capital 1,040.00 (-0.95 %) teesta agro 77.00 (-6.21 %) trl krosaki 1,300.00 (1.96 %) urban tots 92.00 (2.22 %) utkarsh coreinvest 310.00 (3.33 %) vadilal dairy 10.00 vikram solar 285.00 (-1.72 %) vivriti capital 1,150.00 (-0.86 %) waree energies 2,150.00 (-0.46 %)
×

SNS Laboratories Latest Annual Report, Balance Sheet and Financials

SNS Laboratories Limited (SNSLAB) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
SNS Laboratories Limited

SNS Laboratories Limited Balance Sheet (In Rs Thousands)

Particulars

2018

2017

(1)   ASSETS

 

 

Non-current assets

-

-

(a)  Property, Plant and Equipment

 

 

(b)  Capital work-in-progress

 

 

(c)  Investment Property

 

 

(d)  Goodwill

-

-

(e)  Other Intangible assets

-

-

(f)  Intangible assets under development

-

-

(g)   Biological Assets other than bearer plants

-

-

(h)  Financial Assets

-

-

(i)  Investments

-

-

(ii)  Trade receivables

-

-

(iii)  Loans

 

 

(iv)  Others (to be specified)

-

-

(i)  Deferred tax assets (net)

-

-

(j)  Other non-current assets

-

-

(2)   Current assets

-

-

(a)  Inventories

-

-

(b)  Financial Assets

-

-

(i)  Investments

-

-

(ii)  Trade receivables

-

-

(iii)  Cash and cash equivalents

-

16

(iv)  Bank balances other than (iii) above

189

198

(v)  Loans

6

125

(vi)  Others (to be specified)

-

-

(c)  Current Tax Assets (Net)

-

-

(d)  Other current assets

-

-

 

-

-

Total Assets

195

339

EQUITY AND LIABILITIES

 

 

Equity

 

 

(a)  Equity Share Capital

28,625

28,625

(b)  Other Equity

-29,105

-28,648

LIABILITIES

 

 

Non-current liabilities

 

 

(a)  Financial Liabilities

 

 

(i)  Borrowings

 

 

(ii)  Trade payables

 

 

(iii)  Other financial liabilities (other than those specified in item (b), to  be specified)

135 

135 

(b)  Provisions

 

 

(c)  Deferred tax liabilities (Net)

-

-

(d)  Other non-current liabilities

-

-

Current liabilities

   

(a)  Financial Liabilities

-

-

(i)  Borrowings

257

200

(ii)  Trade payables

-

-

(iii)    Other financial liabilities (other than those specified in item (c)

283

27

(b)  Other current liabilities

   

(c)  Provisions

-

-

(d)  Current Tax Liabilities (Net)

 

 

Total Equity and Liabilities

195

339

SNS Laboratories Limited Profit & Loss Statement (In Rs Thousands)

Particulars

2018

2017

 

Income

 

 

 

Revenue From Operations

 

 

 

Other Income

 

 

 

Total Income (I+II)

-

-

 

EXPENSES

 

 

 

Stock-in -Trade and work-in-progress

 

 

 

Employee benefits expense

-

-

 
 

Finance costs

 

 

 

Depreciation and amortization expense

 

 

 

Other expenses

457

385

 

Total expenses

457

385

 

Profit/(loss)   before   exceptional   items and tax

 

 

 

Exceptional Items

 

 

 

Profit/(loss) before tax

-457

-385

 

Tax expense:

 

 

 

(1) Current tax

 

 

 

(2) Deferred tax

 

 

 

Profit (Loss) for the period from continuing operations

-457

-385

 

Profit/(loss) from discontinued Operations

 

 

 

Tax expense of discontinued operations

 

 

 

Profit/(loss) from Discontinued operations

 

 

 

Profit/(loss) for the period

-457

-385

 

Other Comprehensive Income

 

 

 

A (i) Items that will not be reclassified to profit or loss

 

 

 

(ii) Income tax relating to items that will not be reclassified to profit or loss

 

 

 

B (i) Items that will be reclassified to profit or loss

 

 

 

(ii) Income tax relating to items that will be reclassified to profit or loss

 

 

 

Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income

 

 

 

Earnings per equity share

 

 

 

(1) Basic

-

-

 

(2) Diluted

-

-

 

SNS Laboratories Limited Consolidated Cash Flow Statement (In Rs Thousands)

Particulars

2018

2017

Cash flows from operating activities

 

 

Profit before taxation Adjustments for:

-4.57

-3.85

Depreciation

 

 

Working capital changes:

 

 

(Increase) / Decrease in trade and other receivables

-0.16

-0.16

Increase / (Decrease) in Current Liabilities

2.57

3.11

Cash generated from operations

 

 

Interest paid

 

 

Income taxes paid

 

0.25

Dividends paid

 

 

Net cash from operating activities

-1.84

-1.15

Cash flows from investing activities

-

-

Business acquisitions, net of cash acquired

Proceeds from sale of equipment

 

 

Net cash used in investing activities

-

-

Cash flows from financing activities

-

-

Proceeds from issue of share capital

 

 

Proceeds from long-term borrowings

0.57

 

Net cash used in financing activities

0.57

-

Net increase in cash and cash equivalents

-1.28

-1.15

Cash and cash equivalents at beginning of period

3.23

4.38

Cash and cash equivalents at end of period

1.95

3.23

Here is a summary of the Cash Flow Statement for the years 2018 and 2017:

Cash Flows from Operating Activities:

 2018:

1. Profit before taxation Adjustments: -4.57 billion INR

2. Depreciation: Not specified

3. Working Capital Changes:

(Increase) / Decrease in trade and other receivables: -0.16 billion INR

Increase / (Decrease) in Current Liabilities: 2.57 billion INR

4. Cash generated from operations: To be calculated as the sum of the above (excluding depreciation).

5. Interest paid: Not specified

6. Income taxes paid: 0.25 billion INR

7. Dividends paid: Not specified

8. Net cash from operating activities: -1.84 billion INR

 2017:

1. Profit before taxation Adjustments: -3.85 billion INR

2. Depreciation: Not specified

3. Working Capital Changes:

(Increase) / Decrease in trade and other receivables: -0.16 billion INR

Increase / (Decrease) in Current Liabilities: 3.11 billion INR

4. Cash generated from operations: To be calculated as the sum of the above (excluding depreciation).

5. Interest paid: Not specified

6. Income taxes paid: 0.25 billion INR

7. Dividends paid: Not specified

8. Net cash from operating activities: -1.15 billion INR

Cash Flows from Investing Activities:

2018 and 2017:

1. Business acquisitions, net of cash acquired: Not specified

2. Proceeds from sale of equipment: Not specified

3. Net cash used in investing activities: - (Assumed as no information provided)

 

Cash Flows from Financing Activities:

 2018:

1. Proceeds from issue of share capital: Not specified

2. Proceeds from long-term borrowings: 0.57 billion INR

3. Net cash used in financing activities: 0.57 billion INR

2017:

1. Proceeds from issue of share capital: Not specified

2. Proceeds from long-term borrowings: Not specified

3. Net cash used in financing activities: Assumed as 0 (no information provided)

Net Increase in Cash and Cash Equivalents:

2018:

Net increase in cash and cash equivalents: -1.28 billion INR

 2017:

Net increase in cash and cash equivalents: -1.15 billion INR

Cash and Cash Equivalents:

2018:

1. Cash and cash equivalents at beginning of period: 3.23 billion INR

2. Cash and cash equivalents at end of period: 1.95 billion INR

2017:

1. Cash and cash equivalents at beginning of period: 4.38 billion INR

2. Cash and cash equivalents at end of period: 3.23 billion INR

Financial Ratios (NA)

Dividend History (NA)

Annual Report

SNS Laboratories Annual Report 2017-18

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha

News Alert